GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., No. 18-1976 (Fed. Cir. Aug. 5, 2021)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

GlaxoSmithKline LLC and SmithKline Beecham (Cork) Ltd. (collectively, GSK) sued Teva Pharmaceuticals USA, Inc. in the United States District Court for the Dis- trict of Delaware for infringement of claims of GSK’s Reis- sue Patent No. RE40,000. After the jury’s verdict of infringement and its award of damages, the district court granted Teva’s renewed motion for judgment as a matter of law of noninfringement. GlaxoSmithKline LLC v. Te va Pharm. USA, Inc., 313 F. Supp. 3d 582 (D. Del. 2018) (Dist. Ct. Op.).